(Q37992119)

26 August 2017

title

Fenofibric acid for hyperlipidemia (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Alok Saurav

1

1 reference

26 August 2017

Manu Kaushik

series ordinal

2

1 reference

26 August 2017

Syed M Mohiuddin

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

9 March 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

717-722

1 reference

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Do triglycerides provide meaningful information about heart disease risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

Triglycerides and the Risk of Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.658774

10.1517/14656566.2012.658774

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference